Claims for Patent: 8,431,124

Summary for Patent: 8,431,124

Title:	Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)
Abstract:	Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP\'s), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.
Inventor(s):	Bookbinder; Louis H. (San Diego, CA), Kundu; Anirban (San Diego, CA), Frost; Gregory I. (Del Mar, CA)
Assignee:	Halozyme, Inc. (San Diego, CA)
Application Number:	12/386,473
Patent Claims:	1. A method for treating a subject having a disease or condition in which there is an excess of a substrate for a hyaluronidase compared to in the absence of the disease or condition, comprising: administering an amount of a hyaluronidase glycoprotein sufficient to reduce that amount of the substrate to effect treatment, wherein: an excess of substrate is an increased accumulation of the substrate in a diseased tissue or tissue manifesting the condition compared to a normal tissue; the glycoprotein contains at least one sugar moiety that is covalently attached to an asparagine residue of the hyaluronidase polypeptide; is neutral active; and the glycoprotein consists of the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1 or contains amino acid substitutions in the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1, whereby the amino-acid substituted hyaluronidase glycoprotein consists of a sequence that has at least 95% amino acid sequence identity with the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1. 2. The method of claim 1, wherein: the substrate for the hyaluronidase is produced or accumulates in the lumbar spine, thereby causing intradiscal pressure of a herniated disk; and reducing the amount of the substrate effects treatment of the herniated disk. 3. The method of claim 1, wherein the glycoprotein is produced in and secreted from a mammalian cell by a method comprising: introducing an expression vector comprising a polynucleotide that consists of the sequence of nucleotides set forth as nucleotides 106-1446 of SEQ ID NO:6 or degenerates thereof or the sequence of nucleotides set forth in SEQ ID NO:48 or degenerates thereof inserted between flanking sequences in the vector into a mammalian cell; culturing the mammalian cell under conditions whereby the glycoprotein is expressed and secreted by the cell; and recovering a composition comprising the expressed and secreted hyaluronidase glycoprotein. 4. The method of claim 3, wherein the polynucleotide has the sequence of nucleotides set forth in SEQ ID NO:48. 5. The method of claim 1, wherein the glycoprotein consists of the sequence of amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO:1. 6. The method of claim 1, wherein the glycoprotein contains amino acid substitutions in the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1, whereby the amino-acid substituted hyaluronidase glycoprotein consists of a sequence that has at least 95% amino acid sequence identity with the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1. 7. The method of claim 3, wherein the mammalian cell is a CHO cell. 8. The method of claim 1, wherein a composition comprising the glycoprotein that consists of the sequence of amino acids set forth as amino acids 36-482 of SEQ ID NO:1 is administered. 9. The method of claim 1, wherein the glycoprotein is conjugated to a polymer. 10. The method of claim 9, wherein the polymer is a polyethylene glycol (PEG) or a dextran. 11. The method of claim 8, wherein the glycoprotein is conjugated to a polymer. 12. The method of claim 11, wherein the polymer is a polyethylene glycol (PEG) or a dextran. 13. The method of claim 1, wherein the excess substrate is produced from a scar tissue. 14. The method of claim 13, wherein the scar tissue is a glial scar resulting from spinal cord injury, is scar tissue resulting from surgery or is a keloid scar. 15. The method of claim 2, wherein the glycoprotein consists of the sequence of amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO:1. 16. The method of claim 2, wherein the glycoprotein contains amino acid substitutions in the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1, whereby the amino-acid substituted hyaluronidase glycoprotein consists of a sequence that has at least 95% amino acid sequence identity with the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1. 17. The method of claim 2, wherein the glycoprotein is produced in and secreted from a mammalian cell by a method comprising: introducing an expression vector comprising a polynucleotide that consists of the sequence of nucleotides set forth as nucleotides 106-1446 of SEQ ID NO:6 or degenerates thereof or the sequence of nucleotides set forth in SEQ ID NO:48 or degenerates thereof inserted between flanking sequences in the vector into a mammalian cell; culturing the mammalian cell under conditions whereby the glycoprotein is expressed and secreted by the cell; and recovering a composition comprising the expressed and secreted hyaluronidase glycoprotein. 18. The method of claim 2, wherein a composition comprising the glycoprotein that consists of the sequence of amino acids set forth as amino acids 36-482 of SEQ ID NO:1 is administered. 19. A method for treating a herniated disk by chemonucleolysis, comprising contacting the herniated disk with an amount of a hyaluronidase glycoprotein sufficient to effect chemonucleolysis of the hernia, wherein: the glycoprotein contains at least one sugar moiety that is covalently attached to an asparagine residue of the hyaluronidase polypeptide; is neutral active; and the glycoprotein consists of the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1 or contains amino acid substitutions in the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1, whereby the amino-acid substituted hyaluronidase glycoprotein consists of a sequence that has at least 95% amino acid sequence identity with the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1. 20. A method for treating a subject having a disease or condition characterized by an excess of a substrate for a hyaluronidase, comprising: administering an amount of a hyaluronidase glycoprotein sufficient to reduce that amount of the substrate to effect treatment, wherein: an excess of substrate is an increased accumulation of the substrate in a diseased tissue or tissue manifesting the condition compared to a normal tissue; the glycoprotein contains at least one sugar moiety that is covalently attached to an asparagine residue of the hyaluronidase polypeptide; is neutral active; and the glycoprotein: a) consists of a C-terminally truncated polypeptide of SEQ ID NO:1 that includes at least amino acids 36-464 of SEQ ID NO:1, wherein the truncation is at a residue selected from among 477, 478, 479, 480, 481, 482 and 483 of SEQ ID NO:1; or b) the glycoprotein contains amino acid substitutions in the polypeptide of a), whereby the amino-acid substituted hyaluronidase glycoprotein consists of a sequence that has at least 95% amino acid sequence identity with the polypeptide of a); or c) the glycoprotein has more than 99% sequence identity of with the polypeptide of a); or d) the glycoprotein has more than 97% sequence identity with the polypeptide of a), wherein truncation is at residue 483. 21. The method of claim 20, wherein the disease or condition is a scar or herniated disk.

Details for Patent 8,431,124

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	May 05, 2004		2023-03-05
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	December 02, 2004		2023-03-05
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	October 26, 2004		2023-03-05
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	October 25, 2005		2023-03-05
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859	December 02, 2005		2023-03-05

International Patent Family for US Patent 8,431,124

Country	Patent Number	Estimated Expiration
Austria	E448323
Australia	2004218354
Australia	2006216545
Australia	2009245838
Australia	2013202475
Brazil	PI0408116
Brazil	PI0608314